Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 98

Sort by

Sort Order Select

Journal Articles

Phylogenetic Analysis Reveals Distinct Evolutionary Patterns in Multiple Myeloma Patient Derived Xenografts

Nathan Becker, Enze Liu, Parvathi Sudha, Riya Sharma, Travis Johnson, Aneta Mikulasova, Rafat Abonour, Brian A. Walker

Blood (2024) 144 (Supplement 1): 1882.

https://doi.org/10.1182/blood-2024-203953

Published: 2024

Journal Articles

Reconstructing Catastrophic Chromothripsis Events Using Multiomic Data Reveals Their Functional Impact in Multiple Myeloma

Enze Liu, Nathan Becker, Parvathi Sudha, Aneta Mikulasova, Rafat Abonour, Brian A. Walker

Blood (2024) 144 (Supplement 1): 4644.

https://doi.org/10.1182/blood-2024-205167

Published: 2024

Journal Articles

Subclone-Aware Prognosis across Stages of Myeloma Progression and Course of Treatment

Travis Johnson, Enze Liu, Ke Yang, Parvathi Sudha, Vivek S. Chopra, Faiza Zafar, Rafat Abonour, Brian A. Walker

Blood (2024) 144 (Supplement 1): 4657.

https://doi.org/10.1182/blood-2024-211489

Published: 2024

Journal Articles

Multiomics Data Integration in the Complete Myeloma Genome Reveals Frequent Centromeric Rearrangements and Their Epigenomic Consequences

Aneta Mikulasova, Enze Liu, Nathan Becker, Parvathi Sudha, Rafat Abonour, Brian A. Walker

Blood (2024) 144 (Supplement 1): 768.

https://doi.org/10.1182/blood-2024-200043

Published: 2024

Journal Articles

Safety and Efficacy of Teclistamab in a Patient Series with Relapsed/Refractory Multiple Myeloma and Severe Renal Impairment on Dialysis

Nutdanai Roila, Attaya Suvannasankha, Rafat Abonour

Blood (2024) 144 (Supplement 1): 6912.

https://doi.org/10.1182/blood-2024-201209

Published: 2024

Journal Articles

Novel PD-L1 Blocking Peptide with Mitochondrial Targeting Sequence: A Strategy to Counteract Resistance in T-Cell Immunotherapy for Myeloma

Smriti Gurung, Colin Crean, David Lloyd Halladay, Judith L. Anderson, Rafat Abonour, Brian A. Walker, Kelvin P. Lee, John Mitchell Chirgwin, Attaya Suvannasankha

Blood (2024) 144 (Supplement 1): 6861.

https://doi.org/10.1182/blood-2024-211787

Published: 2024

Journal Articles

Characterization of Anthropometric Changes in Patients with Relapsed/Refractory Myeloma Treated with BCMA Bispecific Antibody Teclistamab

Setarah Mohammad Nader, S. Tyler Jines, Christopher Collier, Teresa Zimmers, Rafat Abonour, Sherif Farag, Mohammad Abu Zaid, Kelvin P. Lee, Attaya Suvannasankha

Blood (2023) 142 (Supplement 1): 6683.

https://doi.org/10.1182/blood-2023-182754

Published: 2023

Journal Articles

Unraveling Diverse Mechanisms of Complex Structural Variant Interactions through Multiomic Data in Multiple Myeloma

Enze Liu, Nathan Becker, Parvathi Sudha, Aneta Mikulasova, Mohammad Abu Zaid, Attaya Suvannasankha, Kelvin P. Lee, Rafat Abonour, Brian A. Walker

Blood (2023) 142 (Supplement 1): 641.

https://doi.org/10.1182/blood-2023-186262

Published: 2023

Journal Articles

Phase I First-in-Human Study on the Feasibility, Safety, and Antitumor Activity of CD4-Redirected Chimeric Antigen Receptor (CAR) T-Cell Therapy in Patients with CD4+ T-Cell Malignancies (TCM)

Rita Assi, Nabil Hagag, Sherif Farag, Robert V.B. Emmons, Allie Carter, Magdalena Czader, Rafat Abonour, Lionel Apetoh, Yupo Ma, Huda S. Salman

Blood (2023) 142 (Supplement 1): 6854.

https://doi.org/10.1182/blood-2023-180111

Published: 2023

Journal Articles

Prospective Molecular Characterization of Multiple Myeloma Patient Samples Identifies High-Risk Patients and Informs Treatment Sequences through Resistance Mechanisms to Immunotherapies

Phillip Pham, Parvathi Sudha, Lin Wang, Wen Niu, Cameron Morgan, Cameron Ligocki, Ramzi Al-Azzawi, Reynold Ly, Francesco Vetrini, Magdalena Czader, Marwan Tayeh, Mohammad Abu Zaid, Kelvin P. Lee, Attaya Suvannasankha, Rafat Abonour, Brian A. Walker

Blood (2023) 142 (Supplement 1): 4738.

https://doi.org/10.1182/blood-2023-180116

Published: 2023

Journal Articles

Teclistamab in Relapsed/Refractory Multiple Myeloma: Real-World Outcomes at a Single Academic Center in the Midwest

Adam Stepanovic, Rafat Abonour, Mohammad Abu Zaid, Sherif Farag, Kelvin P. Lee, Attaya Suvannasankha

Blood (2023) 142 (Supplement 1): 7359.

https://doi.org/10.1182/blood-2023-183085

Published: 2023

Journal Articles

A Phase 1, Open-Label, Dose-Escalation and Expansion, Multicenter Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of MT-0169 in Patients with Relapsed or Refractory Multiple Myeloma or Non-Hodgkin Lymphoma

Bhagirathbhai Dholaria, Admasu Mamuye, Diana Yurewicz, Kristina Dabovic, Amy Yuet, Rafat Abonour, Kevin R. Kelly, Timothy J. Voorhees, Dickran Kazandjian

Blood (2022) 140 (Supplement 1): 12621–12622.

https://doi.org/10.1182/blood-2022-168960

Published: 2022

Journal Articles

Outcomes of Second-Line (2L) Triplet+ Regimens in Patients with Relapsed/Refractory Multiple Myeloma (MM) Following Progression after First-Line (1L) Lenalidomide in the Connect® MM Disease Registry

Hans C. Lee, Rafat Abonour, Sikander Ailawadhi, Brian G.M. Durie, Cristina J. Gasparetto, James W. Hardin, Mohit Narang, James Omel, Robert M. Rifkin, Howard Terebelo, Kathleen Toomey, Lynne I. Wagner, Samantha Slaff, Dailan Danforth, Weiyuan Chung, Jasmeet Anand, Edward Yu, Derek Tang, Sundar Jagannath

Blood (2022) 140 (Supplement 1): 13256–13258.

https://doi.org/10.1182/blood-2022-158197

Published: 2022

Journal Articles

Impact of COVID-19 on Treatment Patterns and Management of Multiple Myeloma: Insights from the Connect® MM Registry

Joshua Richter, Sikander Ailawadhi, Hans C. Lee, James W. Hardin, Howard R. Terebelo, Rafat Abonour, Lynne I. Wagner, Brian G.M. Durie, James L. Omel, Mohit Narang, Kathleen Toomey, Robert M. Rifkin, Cristina J. Gasparetto, Edward Yu, Jasmeet Anand, Liang Liu, Ying-Ming Jou, Sundar Jagannath

Blood (2022) 140 (Supplement 1): 8089–8091.

https://doi.org/10.1182/blood-2022-158627

Published: 2022

Journal Articles

Healthcare Utilization Among Patients with Advanced Systemic Light Chain Amyloidosis

Morie A. Gertz, Rafat Abonour, Sarah N. Gibbs, Muriel Finkel, Heather Landau, Suzanne Lentzsch, Grace Lin, Anuj Mahindra, Tiffany P. Quock, Cara A. Rosenbaum, Michael Rosenzweig, Surbhi Sidana, Sascha A. Tuchman, Ronald Witteles, Irina Yermilov, Michael S. Broder

Blood (2022) 140 (Supplement 1): 13129–13131.

https://doi.org/10.1182/blood-2022-156832

Published: 2022

Journal Articles

Fixed Duration Therapy with Daratumumab, Carfilzomib, Lenalidomide and Dexamethasone for High Risk Smoldering Multiple Myeloma-Results of the Ascent Trial

Shaji K Kumar, Melissa Alsina, Betsy Laplant, Ashraf Z. Badros, Al-Ola Abdallah, Rafat Abonour, Erik J Asmus, Binod Dhakal, Cara A. Rosenbaum, Daniel Egan, Manisha Bhutani, Andrzej Jakubowiak, Brian G.M. Durie

Blood (2022) 140 (Supplement 1): 1830–1832.

https://doi.org/10.1182/blood-2022-168930

Published: 2022

Journal Articles

Interim Phase I Clinical Data of FT576 As Monotherapy and in Combination with Daratumumab in Subjects with Relapsed/Refractory Multiple Myeloma

Binod Dhakal, Jesus G. Berdeja, Tara Gregory, Thomas Ly, Cara Bickers, Xingyue Zong, Lilly Wong, Jode P. Goodridge, Sarah Cooley, Bahram Valamehr, Yu-Waye Chu, John Byon, Rafat Abonour

Blood (2022) 140 (Supplement 1): 4586–4587.

https://doi.org/10.1182/blood-2022-166994

Published: 2022

Journal Articles

Patient Derived Xenografts Highlight Mouse-Specific Tumor Evolution Patterns and Genomic Diversity of Multiple Myeloma

Nathan Becker, Enze Liu, Parvathi Sudha, Aneta Mikulasova, Travis S Johnson, Attaya Suvannasankha, Mohammad Issam Abu Zaid, Rafat Abonour, Brian A. Walker

Blood (2022) 140 (Supplement 1): 9970–9971.

https://doi.org/10.1182/blood-2022-157086

Published: 2022

Journal Articles

The Pre-Existing T Cell Landscape Is Associated with Response to High Dose Melphalan and Autologous Stem Cell Transplant in Multiple Myeloma

Mohammad Issam Abu Zaid, Parvathi Sudha, Travis S Johnson, Vivek S. Chopra, Cedric E. Dos Santos, Michael Nixon, Attaya Suvannasankha, Sherif S Farag, Kelvin P. Lee, Rafat Abonour, Brian A. Walker

Blood (2022) 140 (Supplement 1): 9919–9920.

https://doi.org/10.1182/blood-2022-167619

Published: 2022

Journal Articles

Single Cell Multiomic Analysis Reveals Relapsed and Refractory Multiple Myeloma Cells Associated with 1q, TP53 , and PHF19 alterations That Affect Subclonal Chromatin Accessibility

Travis S Johnson, Parvathi Sudha, Enze Liu, Vivek S. Chopra, Cedric E. Dos Santos, Michael Nixon, Kun Huang, Rafat Abonour, Mohammad Issam Abu Zaid, Brian A. Walker

Blood (2022) 140 (Supplement 1): 598–599.

https://doi.org/10.1182/blood-2022-167301

Published: 2022

NARROW

Phylogenetic Analysis Reveals Distinct Evolutionary Patterns in Multiple Myeloma Patient Derived Xenografts

Reconstructing Catastrophic Chromothripsis Events Using Multiomic Data Reveals Their Functional Impact in Multiple Myeloma

Subclone-Aware Prognosis across Stages of Myeloma Progression and Course of Treatment

Multiomics Data Integration in the Complete Myeloma Genome Reveals Frequent Centromeric Rearrangements and Their Epigenomic Consequences

Safety and Efficacy of Teclistamab in a Patient Series with Relapsed/Refractory Multiple Myeloma and Severe Renal Impairment on Dialysis

Novel PD-L1 Blocking Peptide with Mitochondrial Targeting Sequence: A Strategy to Counteract Resistance in T-Cell Immunotherapy for Myeloma

Characterization of Anthropometric Changes in Patients with Relapsed/Refractory Myeloma Treated with BCMA Bispecific Antibody Teclistamab

Unraveling Diverse Mechanisms of Complex Structural Variant Interactions through Multiomic Data in Multiple Myeloma

Phase I First-in-Human Study on the Feasibility, Safety, and Antitumor Activity of CD4-Redirected Chimeric Antigen Receptor (CAR) T-Cell Therapy in Patients with CD4+ T-Cell Malignancies (TCM)

Prospective Molecular Characterization of Multiple Myeloma Patient Samples Identifies High-Risk Patients and Informs Treatment Sequences through Resistance Mechanisms to Immunotherapies

Teclistamab in Relapsed/Refractory Multiple Myeloma: Real-World Outcomes at a Single Academic Center in the Midwest

A Phase 1, Open-Label, Dose-Escalation and Expansion, Multicenter Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of MT-0169 in Patients with Relapsed or Refractory Multiple Myeloma or Non-Hodgkin Lymphoma

Outcomes of Second-Line (2L) Triplet+ Regimens in Patients with Relapsed/Refractory Multiple Myeloma (MM) Following Progression after First-Line (1L) Lenalidomide in the Connect® MM Disease Registry

Impact of COVID-19 on Treatment Patterns and Management of Multiple Myeloma: Insights from the Connect® MM Registry

Healthcare Utilization Among Patients with Advanced Systemic Light Chain Amyloidosis

Fixed Duration Therapy with Daratumumab, Carfilzomib, Lenalidomide and Dexamethasone for High Risk Smoldering Multiple Myeloma-Results of the Ascent Trial

Interim Phase I Clinical Data of FT576 As Monotherapy and in Combination with Daratumumab in Subjects with Relapsed/Refractory Multiple Myeloma

Patient Derived Xenografts Highlight Mouse-Specific Tumor Evolution Patterns and Genomic Diversity of Multiple Myeloma

The Pre-Existing T Cell Landscape Is Associated with Response to High Dose Melphalan and Autologous Stem Cell Transplant in Multiple Myeloma

Single Cell Multiomic Analysis Reveals Relapsed and Refractory Multiple Myeloma Cells Associated with 1q, TP53 , and PHF19 alterations That Affect Subclonal Chromatin Accessibility

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only